Hackensack Meridian Health Observational Study Demonstrates Lack of Efficacy of Hydroxychloroquine Among Hospitalized COVID-19 Patients But Finds First Treatment (tocilizumab) to Improve Surv
Real time analysis via RE-COV-RY (Real world Evidence COVid-19 RegistrY)?accelerates identification of effective therapies to fight COVID -19
Hackensack Meridian?Health, New Jersey?s largest and most comprehensive health network, has utilized its large observational database of more than 3,000 hospitalized COVID-19 patients to show that the touted malaria treatment, hydroxychloroquine, does not improve survival for hospitalized patients. However, another drug, tocilizumab, appears to improve survival among critically ill intensive care unit (ICU) patients.? If confirmed, tocilizumab would become the first medication improving survival from COVID-19.
These major findings were released today on the online platform medRxiv, which allow researchers to share critical scientific information rapidly prior to publication in peer-reviewed journals. ?Given the potential lifesaving findings of tocilizumab the Hackensack Meridian?Health?researchers believe that sharing this information rapidly is important.? The results are based on the new data analysis platform ? the HMH Universal Observational Database for COVID-19, or RECOVERY, which compiles outcomes from 13 Hackensack Meridian?Health?hospitals throughout New Jersey. This database enhances the understanding of this disease and helps rapidly identify effective therapies.
?I am so proud of our Hackensack Meridian?Health?clinical and research teams who are helping to tackle this unprecedented global challenge,? said?Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian?Health.??This groundbreaking study will help our hospitals, as well as hospitals throughout the world, better understand the effectiveness of certain forms of treatment and the impact of certain risk factors. Our researchers? observations that tocilizumab may improve survival among the most critically ill could alter the course of the pandemic if confirmed in randomized trials ? and Hackensack Meridian?Health?is participating in those randomized trials as well.?
The outcomes division of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center, under the leadership of Dr. Stuart Goldberg and Dr. Andrew Ip, created a database to guide the analysis of more than 3,000 patients admitted to Hackensack Meridian?Health?facilities for urgent care.
?As our country and the world struggles with the adverse health effects and economic consequences of COVID-19, Hackensack Meridian?Health?realizes it is vital to rapidly learn all we can from the experiences of the patients in our care,? said?Stuart Goldberg, M.D., a hematologist/oncologist and chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey.
Results from the study include the following:
- Among 2,512 hospitalized patients with COVID-19, 76 percent received at least one dose of hydroxychloroquine and 59 percent received hydroxychloroquine with azithromycin.
- After adjusting for imbalances via propensity modeling, compared to receiving no hydroxychloroquine, there was no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospital stay.
- Among 547 ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival rate: 56 percent who received the drug compared to 46 percent who did not receive the therapy, and a propensity adjusted hazard ratio 0.76.